
The Myth of “Normal” in Women’s Health: Clue CEO Rhiannon White on Building a Business Around Women’s Real Needs
Dr. Dereck Mush, MD, MBAHertility is a London-based reproductive health company that offers at-home hormone and fertility tests.
Hertility's flagship Hormone & Fertility Test combines an online health assessment, a finger-prick blood sample taken at home and reviewed in a lab, and a results dashboard where a reproductive health specialist explains the findings and suggests next steps. The company also offers consultations with in-house specialists and conducts research into reproductive health. Hertility was founded in 2019 by Dr. Helen O'Neill (CEO), Dr. Natalie Getreu (COO) and Deirdre O'Neill (CCO). The company has raised more than $14 million, including a 4.2 million pound seed round in 2021 led by LocalGlobe with Venrex, and a community round in 2023 of about $7.5 million from more than 1,000 individual investors.
How Hertility got here, step by step.
2021
Hertility raised a 4.2 million pound seed round led by LocalGlobe, with Venrex participating.
2023
Hertility raised about $7.5 million from more than 1,000 individual investors in a community round.
October 2024
Emma Watson invested in Hertility, taking the company's total funding past $14 million, TechCrunch reported.

Dr. Dereck Mush, MD, MBAMentions Hertility
Related companies
Your daily HealthTech Signal
Get the latest HealthTech news, understand why it matters, and see where the industry is headed.



Read by teams at companies like: